Analysts Offer Insights on Healthcare Companies: Incyte Corp (NASDAQ: INCY), Strongbridge Biopharma Plc (NASDAQ: SBBP) and Pfizer (NYSE: PFE)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte Corp (NASDAQ: INCY), Strongbridge Biopharma Plc (NASDAQ: SBBP) and Pfizer (NYSE: PFE).

Incyte Corp (NASDAQ: INCY)

Jefferies analyst Biren Amin reiterated a Buy rating on Incyte Corp (NASDAQ: INCY) yesterday and set a price target of $148. The company’s shares closed yesterday at $120.49.

According to TipRanks.com, Amin is a 3-star analyst with an average return of 2.4% and a 49.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Lion Biotechnologies Inc, and Bellicum Pharmaceuticals.

Currently, the analyst consensus on Incyte Corp is Strong Buy and the average price target is $149.08, representing a 23.7% upside.

In a report issued on May 4, Cowen & Co. also reiterated a Buy rating on the stock.
Strongbridge Biopharma Plc (NASDAQ: SBBP)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP) yesterday and set a price target of $18. The company’s shares closed yesterday at $4.55.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.7% and a 49.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Strongbridge Biopharma Plc has an analyst consensus of Moderate Buy, with a price target consensus of $18.

Pfizer (NYSE: PFE)

In a report released yesterday, Eun Yang from Jefferies reiterated a Hold rating on Pfizer (NYSE: PFE), with a price target of $35. The company’s shares closed yesterday at $32.23.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 3.0% and a 50.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Pfizer is Hold and the average price target is $35.33, representing a 9.6% upside.

In a report issued on May 4, BMO Capital also reiterated a Hold rating on the stock with a $33 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.